NCT06408311
Safety of ENC-201-CED ENCRT
A Safety and Tolerability Study of ENC=201-CED in Participants With Type 1 Diabetes Receiving Islet Infusion
Encellin·Phase 1·ClinicalTrials.gov·combination productRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Diabetes Mellitus, Type 1
- Drug/Device/Intervention
- ENC-201-CED hPI
- Study type
- Interventional
- Intervention type
- combination product
Sponsor & location
- Primary sponsor
- Encellin
- Location
- Montréal, Canada
Timeline & enrollment
- Phase
- Phase 1
- Start date
- May 01, 2024
- End date
- Jun 30, 2026
- Enrollment
- 10 participants
Primary outcome
Safety
Summary
The purpose of the study is to evaluate the safety and tolerability of ENC-201-CED in a
 subcutaneous space in patients with Type I diabetes.
ICD-10 classifications
Type 1 diabetes mellitusType 1 diabetes mellitus with unspecified complicationsType 1 diabetes mellitus with other specified complicationsType 1 diabetes mellitus without complicationsType 1 diabetes mellitus with multiple complications
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06408311
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06408311 through Pure Global AI's free database. This Phase 1 trial is sponsored by Encellin and is currently Recruiting. The study focuses on Diabetes Mellitus, Type 1. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.